Literature DB >> 16971226

5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results.

Salvatore Pucciarelli1, Emanuele Urso, Gian Luca DeSalvo, Carlo Aschele, Maria Luisa Friso, Massimo Rugge, Paola Toppan, Andrea Bruttocao, Giuliano Fabris, Benito Ferraro, Sara Lonardi, Mauro Frego, Cristiano Finco, Mario Lise, Donato Nitti.   

Abstract

BACKGROUND: We undertook this study to evaluate early surgical complications and long-term results after preoperative radiotherapy and chemotherapy (RCT) using 5-fluorouracil (5-FU) and oxaliplatin (OXA) for rectal cancer.
METHODS: Forty six TNM stage II-III rectal cancer patients were studied, who were given preoperative RT (50.4 Gy/28 fractions) combined with 5-FU (200-225 mg/m(2)/day by continuous venous infusion) and weekly OXA (25-60 mg/m(2)). Major complications and reoperations were recorded overall, whereas outcome analyses were performed only for patients who received the recommended regimen dosage.
RESULTS: Forty three patients (M:F, 25:18; median age 59 years) were available for analysis. All patients received the planned RT dose. There were no postoperative deaths; seven patients had early major surgical complications, four requiring re-operation. One additional patient had a second surgical procedure due to a duodenal fistula complicating the resection of an aortic aneurysm performed concomitantly with rectal cancer surgery. At a median follow-up of 49 months, two of the 23 patients treated at the recommended doses developed recurrence (one local, and one local and distant), and two died of cancer progression. Following the Kaplan-Meier method, the estimated 5-year overall and disease-free survival rates were 92 and 89%, respectively.
CONCLUSIONS: The preoperative RCT regimen used in the present study incurs a low rate of recurrence with an acceptable surgical morbidity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16971226     DOI: 10.1016/j.arcmed.2006.04.008

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  5 in total

1.  Functional outcomes after TEM in patients with complete clinical response after neoadjuvant chemoradiotherapy.

Authors:  Roberto Ghiselli; Monica Ortenzi; Luca Cardinali; Edlira Skrami; Rosaria Gesuita; Mario Guerrieri
Journal:  Surg Endosc       Date:  2016-11-11       Impact factor: 4.584

2.  Transanal endoscopic microsurgery after neoadjuvant radiochemotherapy for locally advanced extraperitoneal rectal cancer: short-term morbidity and functional outcome.

Authors:  C Coco; G Rizzo; C Mattana; M A Gambacorta; A Verbo; B Barbaro; F M Vecchio; D P Pafundi; M G Mastromarino; V Valentini
Journal:  Surg Endosc       Date:  2013-02-13       Impact factor: 4.584

3.  Addition of oxaliplatin to capecitabine-based preoperative chemoradiotherapy for locally advanced rectal cancer: Long-term outcome of a phase II study.

Authors:  Jianhong Peng; Junzhong Lin; Zhifan Zeng; Xiaojun Wu; Gong Chen; Liren Li; Zhenhai Lu; Peirong Ding; Desen Wan; Zhizhong Pan
Journal:  Oncol Lett       Date:  2017-08-17       Impact factor: 2.967

4.  Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study.

Authors:  Sm Iles; Sw Gollins; S Susnerwala; B Haylock; S Myint; A Biswas; R Swindell; E Levine
Journal:  Br J Cancer       Date:  2008-03-18       Impact factor: 7.640

5.  Downregulation of SMC1A inhibits growth and increases apoptosis and chemosensitivity of colorectal cancer cells.

Authors:  Jin Li; Wanting Feng; Longbang Chen; Jingdong He
Journal:  J Int Med Res       Date:  2015-12-03       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.